A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients.

Cancer Research
L RossoE Aboagye

Abstract

Difficulties in direct measurement of drug concentrations in human tissues have hampered the understanding of drug accumulation in tumors and normal tissues. We propose a new system analysis modeling approach to characterize drug distribution in tissues based on human positron emission tomography (PET) data. The PET system analysis method was applied to temozolomide, an important alkylating agent used in the treatment of brain tumors, as part of standard temozolomide treatment regimens in patients. The system analysis technique, embodied in the convolution integral, generated an impulse response function that, when convolved with temozolomide plasma concentration input functions, yielded predicted normal brain and brain tumor temozolomide concentration profiles for different temozolomide dosing regimens (75-200 mg/m(2)/d). Predicted peak concentrations of temozolomide ranged from 2.9 to 6.7 microg/mL in human glioma tumors and from 1.8 to 3.7 microg/mL in normal brain, with the total drug exposure, as indicated by the tissue/plasma area under the curve ratio, being about 1.3 in tumor compared with 0.9 in normal brain. The higher temozolomide exposures in brain tumor relative to normal brain were attributed to breakdown of the b...Continue Reading

References

May 1, 1994·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·F TurkheimerK Schmidt
Jan 1, 1993·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·V J Cunningham, T Jones
Jan 1, 1993·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S M O'ReillyP Lewis
Nov 11, 1998·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·F TurkheimerK Schmidt
Aug 5, 1999·Journal of the National Cancer Institute·K A GelmonP Workman
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L A HammondE K Rowinsky
Jul 13, 2002·Expert Review of Anticancer Therapy·S J Danson, M R Middleton
Feb 7, 2003·Fundamental & Clinical Pharmacology·Annick Rousseau, Pierre Marquet
Mar 18, 2003·Journal of Clinical Pharmacology·Honghui Zhou
Jan 2, 2004·Physics in Medicine and Biology·Federico E TurkheimerVincent J Cunningham
Jan 27, 2004·Pharmacotherapy·Michelle A RudekSharyn D Baker
Jun 3, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sandrine OstermannRoger Stupp
Dec 9, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·James M GalloPing Guo
Feb 19, 2005·Critical Reviews in Oncology/hematology·M J PayneM R Middleton
May 4, 2006·Journal of the National Cancer Institute·Paul WorkmanUNKNOWN Cancer Research UK Pharmacodynamic/Pharmacokinetic Technologies Advisory Committee
Aug 24, 2006·Expert Review of Anticancer Therapy·Nicole Mutter, Roger Stupp
Jan 11, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joseph A DiMasi, Henry G Grabowski
Jul 20, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Qingyu ZhouJames M Gallo

❮ Previous
Next ❯

Citations

Feb 28, 2013·Journal of Pharmacokinetics and Pharmacodynamics·Giampaolo Tomasi, Eric O Aboagye
Aug 16, 2011·Molecular Imaging and Biology : MIB : the Official Publication of the Academy of Molecular Imaging·Giampaolo TomasiEric Aboagye
Jun 17, 2011·Expert Reviews in Molecular Medicine·Sagar AgarwalWilliam F Elmquist
Nov 15, 2012·Nature Reviews. Clinical Oncology·Andrew C PeetAdam D Waldman
Dec 17, 2011·Journal of the National Cancer Institute·Ryuichi KanaiRobert L Martuza
Sep 28, 2012·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Sagar AgarwalWilliam F Elmquist
Oct 29, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jana PortnowTimothy W Synold
Mar 1, 2013·BMC Complementary and Alternative Medicine·Renata Markiewicz-ŻukowskaHalina Car
Oct 13, 2011·Molecular Cancer·Dagmar BeierChristoph P Beier
Jul 14, 2010·Targeted Oncology·Astrid A M van der VeldtEpie Boven
Aug 21, 2014·Neuro-oncology·David A ReardonUNKNOWN BI 1200 36 Trial Group and the Canadian Brain Tumour Consortium
Jul 1, 2014·Journal of Controlled Release : Official Journal of the Controlled Release Society·Elizabeth NanceRichard J Price
Jun 2, 2015·Expert Review of Neurotherapeutics·Brenda AuffingerMaciej S Lesniak
Apr 28, 2011·Expert Opinion on Drug Metabolism & Toxicology·Andrew D GreenhalghJames P Galea
Aug 1, 2014·Advanced Drug Delivery Reviews·Olivier KeunenFrits Thorsen
Jan 1, 2013·PET Clinics·Charalampos Tsoumpas, Anastasios Gaitanis
Aug 21, 2012·Current Opinion in Pharmacology·Giampaolo Tomasi, Lula Rosso
Jul 4, 2012·Neurosurgery Clinics of North America·Marko SpasicIsaac Yang
Mar 24, 2012·Neurosurgery Clinics of North America·Daniel T NagasawaIsaac Yang
Jan 10, 2012·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Quang-Dé NguyenEric O Aboagye
Jan 4, 2012·Pharmacology & Therapeutics·Teresa W-M FanAndrew N Lane
Jul 19, 2011·Hematology/oncology Clinics of North America·Katherine M KrajewskiIvan Pedrosa
May 17, 2011·Current Opinion in Pharmacology·Paul M MatthewsRoger Gunn
Sep 17, 2009·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Miho ShidaharaTetsuya Suhara
Aug 16, 2011·British Journal of Clinical Pharmacology·Paul M MatthewsRoger N Gunn
Dec 24, 2010·British Journal of Pharmacology·Rohini Sharma, Eric Aboagye
Sep 26, 2015·Neuro-oncology·Victor A LevinRussell C Petter
Feb 27, 2015·Biomechanics and Modeling in Mechanobiology·Alain GorielyEllen Kuhl
Apr 18, 2015·Journal of Translational Medicine·Rutger K BalversSieger Leenstra
Jun 23, 2010·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Eva HühnPeter Langguth
Apr 14, 2015·BioMed Research International·Arijit BhowmikMrinal Kanti Ghosh
May 16, 2014·Clinical Pharmacology and Therapeutics·I Fuso NeriniM D'Incalci
Oct 7, 2016·Interface Focus·Ahmed BoujelbenMark A J Chaplain
Oct 7, 2016·PloS One·Martin J HicksRonald G Crystal
May 24, 2011·Pharmacological Reports : PR·Joanna Jakubowicz-GilWojciech Rzeski
Mar 24, 2015·Chemical Communications : Chem Comm·Yanfeng ZhangJianjun Cheng

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

Blood Brain Barrier Regulation in Health & Disease

The blood brain barrier is essential in regulating the movement of molecules and substances in and out of the brain. Disruption to the blood brain barrier and changes in permeability allow pathogens and inflammatory molecules to cross the barrier and may play a part in the pathogenesis of neurodegenerative disorders. Here is the latest research in this field.

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.